Desmopressin for the Treatment of Orthostatic Hypotension and Excessive Nighttime Urination in Parkinson’s Disease
A Double-Blind, Placebo-controlled Crossover Clinical Trial of Desmopressin for the Treatment of Orthostatic Hypotension and Nocturia in Parkinson’s Disease
John O'Sullivan
20 participants
Apr 6, 2009
Interventional
Conditions
Summary
We plan to study 20 patients with idiopathic Parkinson's disease with complications of orthostatic hypotension and nocturia. In an 8 week double-blinded, crossover study design, we will study the effects of oral desmopressin (or matching placebo) on orthostatic hypotension, nocturia, and sleep.
Eligibility
Inclusion Criteria3
- Parkinson's disease
- Orthostatic hypotension (blood pressure drop with standing)
- A need to empty the bladder 2 or more times at night
Exclusion Criteria3
- History of renal failure, congestive heart failure, or cirrhosis
- A history of low blood sodium
- Dementia
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Subjects will start with either nightly placebo or oral desmopressin for three weeks. After a washout period of one week of no medication, they will then switch to the therapy they have not tried for another three weeks. Subjects taking desmopressin will begin with a 100 mcg nightly dose. If this is tolerated, after one week they will increase to 200 mcg nightly, which they will take for two weeks.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000080224